

PE54, a pan-ebola chimeric human IgG1

Catalog #: 0200-004

Description:

Protein A purified, human monoclonal antibody reactive to Ebola virus (EBOV), Sudan virus (SUDV) and Bundibugyo virus (BDBV) glycoproteins.

Immunogen/ Target:

Filovirus recombinant glycoproteins and virus-like particles.

Formulation & Storage: -80°C long term.
Recommended to dispense into single-use aliquots to avoid repeated freeze/thaw cycles.

Notes & Usage Guidelines:

Clonality/ Isotype:

Host:


ELISA: Assay-dependent dilution

WB:

Applications


ELISA Data:

Plate was coated with recombinant EBOV, SUDV or BDBV glycoprotein at 100 ng/well. Washed plates were incubated with antibody starting at 100 µg/mL, followed by semi-log dilutions. Detection was achieved using anti-human IgG (H+L)-HRP conjugate and TMB substrate. OD₆₅₀ is reported above.



Neutralization Data:

Antibody starting at 20 µg/mL, followed by semi-log dilutions was incubated with vesicular stomatitis viruses (VSV) pseudotyped with EBOV, SUDV or BDBV glycoprotein and expressing luciferase, for one hour prior to infectivity on Vero cell monolayers. Infectivity was determined 24 hours post infection by quantification of luciferase signal. Percent neutralization was calculated based on the controls.



Certificate of analysis:

A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information. For older lots, refer to the applicable certificate of analysis that may be requested at products@ibtbioservices.com.

Related Products:

IBT provides a wide array of antibodies, recombinant proteins, and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, LLC.

Copyright 2026. Integrated BioTherapeutics, LLC. All rights reserved.